Medicus 2014;23(1):31-46
45
LITERATURA
1. Katzung i sur. Basic and Clinical Pharmacology. McGraw Hill Me-
dical. 12. izd., 2011.
2. Brunton L, Chabner B, Knollman B. Goodman and Gilman’s Phar-
macological Basis of Therapeutics. McGraw Hill Professional. 12.
izd., 2012.
3. Warner TD, Giuliano F, Vojnovic I i sur. Nonsteroid drug selecti-
vities for cyclo-oxygenase-1 rather than cyclo-oxygenase-2 are
associated with human gastrointestinal toxicity: a full in vitro
analysis. Proc Natl Acad Sci USA 1999;96:7563–8.
4. Furst DE. Meloxicam: selective COX-2 inhibition in clinical practi-
ce. Semin Arthritis Rheum 1997; 26 Suppl 1:21–7.
5. Silverstein FE, Faich G, Goldstein JL i sur. Gastrointestinal toxi-
city with celecoxib vs nonsteroidal anti-inflammatory drugs for
osteoarthritis and rheumatoid arthritis: the CLASS study: A ran-
domized controlled trial. Celecoxib Long-term Arthritis Safety
Study. JAMA 2000;284:1247–55.
6. Langman MJ, Jensen DM, Watson DJ i sur. Adverse upper ga-
strointestinal effects of rofecoxib compared with NSAIDs. JAMA
1999;282:1929–33.
7. García Rodríguez LA, Barreales Tolosa L. Risk of upper gastrointe-
stinal complications among users of traditional NSAIDs and COXI-
Bs in the general population. Gastroenterology 2007;132:498–506.
8. Hippisley-Cox J, Coupland C, Logan R. Risk of adverse gastrointe-
stinal outcomes in patients taking cyclo-oxygenase-2 inhibitors or
conventional non-steroidal anti-inflammatory drugs: population
based nested case-control analysis. BMJ 2005;331:1310–6.
9. Lenzer J. FDA advisers warn: COX 2 inhibitors increase risk of he-
art attack and stroke. BMJ 2005;330:440.
10. Jüni P, Nartey L, Reichenbach S i sur. Risk of cardiovascu-
lar events and rofecoxib: cumulative meta-analysis. Lancet
2004;364:2021–9.
11. Dieppe PA, Ebrahim S, Martin RM, Jüni P. Lessons from the with-
drawal of rofecoxib. BMJ 2004;329:867–8.
12. Bresalier RS, Sandler RS, Quan H i sur. Cardiovascular events
associated with rofecoxib in colorectal adenoma chemopreven-
tion trial. N Engl J Med 2005;352:1092–102.
13. European Medicines Agency. Celecoxib (2011). Dostupno na:
-
nes/human/referrals/Celecoxib/human_referral_000145.jsp. Da-
tum pristupa: 17.2.2014.
14. Trelle S, Reichenbach S, Wandel S i sur.
Cardiovascular safety of non-steroidal anti-inflammatory drugs:
network meta-analysis. BMJ 2011;342:c7086.
15. European Medicines Agency finalises review of recent published
data on cardiovascular safety of NSAIDs. Dostupno na: http://
-
man/public_health_alerts/2012/10/human_pha_detail_000067.
jsp&mid. Datum pristupa: 17.2.2014.
16. Lanas A, García-Rodríguez LA, Arroyo MT i sur; Asociación
Española de Gastroenterología. Risk of upper gastrointestinal
ulcer bleeding associated with selective cyclo-oxygenase-2 inhi-
bitors, traditional non-aspirin non-steroidal anti-inflammatory
drugs, aspirin and combinations. Gut 2006;55:1731–8.
17. Langman MJ, Weil J, Wainwright P i sur. Risks of bleeding peptic
ulcer associated with individual non-steroidal anti-inflamma-
tory drugs. Lancet 1994;343:1075–8.
18. Henry D, Lim LL, Garcia Rodriguez LA i sur. Variability in risk of
gastrointestinal complications with individual non-steroidal an-
ti-inflammatory drugs: results of a collaborative meta-analysis.
BMJ 1996;312:1563–6.
19. García Rodríguez LA, Jick H. Risk of upper gastrointestinal blee-
ding and perforation associated with individual non-steroidal
anti-inflammatory drugs. Lancet 1994;343:769–72.
20. Lewis SC, LangmanMJ, Laporte JR i sur. Dose-response relation-
ships between individual nonaspirin nonsteroidal anti-inflam-
matory drugs (NANSAIDs) and serious upper gastrointestinal
bleeding: a meta-analysis based on individual patient data. Br J
Clin Pharmacol 2002;54:320–6.
21. Floor-Schreudering A, Smet PA, Buurma H i sur. NSAID-an-
tihypertensive drug interactions: Which outpatients are at risk
for a rise in systolic blood pressure? Eur J Prev Cardiol 2013 doi:
10.1177/2047487313505243.
22. Briggs i sur. Drug in pregnancy and lactation. 7. izd. Lippincott,
Williams and Wilkins 2005.
23. European Medicines Agency. Diclofenac-containing medicines.
Dostupno na:
l=pages/medicines/human/referrals/Diclofenac-containing_
medicines/human_referral_prac_000009.jsp&mid=WC0b01ac-
05805c516f. Datum pristupa: 17.2.2014.
24. McGettigan P, Henry D. Cardiovascular risk with non-steroidal
anti-inflammatory drugs: systematic review of population-based
controlled observational studies. PLoS Med 2011;8:e1001098.
25. Hrvatska agencija za lijekove i medicinske proizvode. Baza lije-
kova. Dostupno na:
Da-
tum pristupa: 17.2.2014.
26. MacDonald TM, Wei L. Effect of ibuprofen on cardioprotective
effect of aspirin. Lancet 2003;361:573–4.
27. Vesterqvist O, Gréen K. Effects of naproxen on the in vivo synthe-
sis of thromboxane and prostacyclin in man. Eur J Clin Pharma-
col 1989;37:563–5.
28. Rx list. The Internet drug index. Dostupno na:
.
Datum pristupa: 17.2.2014.
29. Electronic Medicines Compendium (cMC). Dostupno na: http://
/. Datum pristupa: 17.2.2014.
30. European Medicines Agency recommends restricted use for pi-
roxicam. European Medicine Agency, 2007. Dostupno na: http://
-
ase/2009/11/WC500012655.pdf. Datum pristupa: 15.11.2013.
31. Castellsague J, Riera-Guardia N, Calingaert B i sur; Safety of
Non-Steroidal Anti-Inflammatory Drugs (the SOS project). Indi-
vidual NSAIDs and upper gastrointestinal complications: a syste-
matic review andmeta-analysis of observational studies (the SOS
project). Drug Saf 2012;35:1127–46.
Farmakokinetika i farmakodinamika analgetika
